Revenue segments as reported by the company.

MedSurg and Neurotechnology

Orthopaedics and Spine

Orthopaedics

MedSurg

Neurotechnology and Spine

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research, development and engineering

Selling, general and administrative

Recall charges

Amortization of intangible assets

Goodwill impairment

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Stryker

MAKO was a publicly traded medical device company based in Florida. On September 25, 2013, the Board of Directors of Mako Surgical accepted a deal to be acquired by Stryker for $1.65B. The deal closed in December 2013. The company manufactures and markets surgical robotic arm assistance platforms, most notably the RIO as well as orthopedic implants used by orthopedic surgeons for use in partial knee and total hip arthroplasty. They are known for their intellectual property of devices and have over 300 U.S. and foreign patents and patent applications.

MAKO Surgical Corp

Stryker Corp. is a medical technology company, which engages in the provision of products and services that help improve patient and healthcare outcomes. It operates under the MedSurg and Neurotechnology, and Orthopaedics and Spine segments. The MedSurg and Neurotechnology segment includes surgical equipment and navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment, intensive care disposable products, clinical communication, workflow solutions, products for the treatment of acute ischemic and hemorrhagic stroke, traditional brain, and open skull based surgical procedures, orthobiologic, and biosurgery. The Orthopaedics and Spine segment focuses on implants used in hip and knee joint replacements and trauma and extremity surgeries, and cervical, thoracolumbar, and interbody systems used in spinal injury, deformity, and degenerative therapies. The company was founded by Homer H. Stryker in 1941 and is headquartered in Portage, MI.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Stryker (SYK) exceeds Q4 expectations, poised for growth in 2023

Stryker (SYK) delivered exceptional financial results in Q4 2022, surpassing expectations and demonstrating resilience amid challenges. The company is well-positioned for growth with a strong pipeline of products and a focus on margin expansion. Despite ongoing market complexities, Stryker remains optimistic about its future performance.

Stryker reports robust Q1 results and optimistic outlook for 2023

Stryker's strong Q1 performance driven by organic sales growth and increased EPS, with positive outlook for the full year.
Company recognized for workplace excellence, leading in robotics, and expecting growth in medical division.
Challenges include supply chain uncertainties, margin impacts, and market disruptions, but opportunities lie in stakeholder engagement and business expansion.
Overall, Stryker remains focused on innovation, debt reduction, and strategic acquisitions for future growth.

Stryker reports stellar Q2 results, eyes international growth opportunities

Stryker's Q2 performance reflects robust sales growth, margin improvement, and strategic acquisitions driving financial strength.
While facing challenges in the U.S. market and competitive landscapes, Stryker's focus on innovation and international growth presents promising opportunities.
The company's financial resilience, debt reduction strategy, and upcoming product launches position Stryker for sustained success and market expansion.
Overall, Stryker's strong performance, coupled with a focus on innovation and strategic growth initiatives, sets a positive trajectory for future success.

Stryker reports robust Q3 earnings, eyes international growth and M&A

Stryker's Q3 performance reflects strong sales growth and earnings increase, driven by key segments and product lines. Challenges include market competition and potential shifts in procedure trends, while opportunities exist in international expansion and strategic acquisitions.

Stryker exceeds $20B in sales, eyes continued growth and innovation

Stryker's Q4 performance showcased strong sales growth, margin expansion, and successful acquisitions, positioning the company for continued success.
While facing challenges in pricing and potential regulatory impacts, Stryker's focus on innovation and strategic growth initiatives presents promising opportunities.
The company's robust pipeline of innovative products and successful integration efforts highlight its resilience and potential for sustained growth.
With a solid financial foundation and strategic vision, Stryker is well-positioned to capitalize on market opportunities and drive future profitability.

Stryker reports strong Q1 growth, eyes international expansion opportunities

Stryker's Q1 2024 earnings call reflects strong performance, with double-digit organic sales growth and increased guidance for the full year.
The company's focus on innovation, successful acquisitions, and market recognition position it well for future growth and leadership in key segments.
While facing challenges like regulatory delays and market dependencies, Stryker remains optimistic about meeting targets and driving growth through new products and acquisitions.
Opportunities in international expansion, AI solutions, and continued market growth present avenues for sustained success and market leadership for Stryker.

Stryker reports robust Q2 earnings, raises 2024 outlook on acquisitions and margin expansion

Stryker's strong Q2 performance, strategic acquisitions, and focus on margin expansion position the company for continued growth. Despite challenges like foreign exchange rates and market softness in certain segments, Stryker's product strength, innovation pipeline, and international growth opportunities offer a positive outlook. With a commitment to driving margins and expanding its product portfolio, Stryker remains poised for sustained success in the medical technology industry.

Stryker reports robust Q3 performance with strong growth and strategic acquisitions

Stryker's Q3 showcased strong organic sales and EPS growth, driven by MedSurg and Neurotechnology segments.
Strategic acquisitions, record Mako installations, and operational efficiency improvements underpin performance.
Challenges in the ischemic stroke segment and competitor actions pose risks, while pricing trends and margin efficiencies are under scrutiny.
Opportunities lie in M&A expansion, growth in high-demand areas, and sustained market momentum.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Stryker (SYK) could produce exceptional returns because of its solid growth attributes.

Is Stryker (SYK) a Solid Growth Stock? 3 Reasons to Think " Yes "

Stryker (SYK) reported earnings 30 days ago. What's next for the stock?

Stryker (SYK) Down 4.3% Since Last Earnings Report: Can It Rebound?

Kalamazoo, Michigan, Feb.  25, 2020  (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) ) will participate in the Cowen 40th Annual Health Care Conference on Tuesday, March 3, 2020 at the Boston Marriott Copley Place in Boston, Massachusetts. 

Stryker to participate in Cowen 40th Annual Health Care Conference

Kalamazoo, Michigan, Feb.  25, 2020  (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that Lisa Skeete Tatum has been nominated for election to the company’s Board of Directors at Stryker’s 2020 Annual Meeting of Shareholders, which will be held on May 5, 2020.

Stryker announces nomination of new Director, Lisa Skeete Tatum

Stryker Humming Along, But Seems To Be Straining The Sell-Side

Stryker's (SYK) fourth-quarter earnings gain from higher revenues, solid segmental performance and strong organic growth across businesses benefit.

Stryker (SYK) Q4 Earnings and Revenues Surpass Estimates

Stryker Corporation (Stryker Corporation) CEO Kevin Lobo on Q4 2019 Results - Earnings Call Transcript

Stryker (SYK) delivered earnings and revenue surprises of 1.22% and 0.74%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Stryker (SYK) Beats Q4 Earnings and Revenue Estimates

Stryker stock jumped late Tuesday after the medical-products company reported adjusted profit of $2.49 per share on $4.13 billion in sales for its fourth quarter ended Dec. 31, 2019.

Stryker Stock Moves Closer To A Breakout As Fourth Quarter Tops Views

Rockwell Automation

Raytheon

Zebra Technologies

The global robotics market is expected to see a CAGR of 25% between 2019 and 2024 on increased human and machine interaction.

Robotics to Take Centerstage in 2020: 5 Stocks in Focus

Intuit

Stryker and Intuit may have small dividend yields, but their dividend payouts are growing rapidly.

2 Stocks With Double-Digit Dividend Growth

Intuitive Surgical

Medtronic

With minimally invasive surgery gaining momentum, these stocks are poised to capitalize on the market prospects.

Minimally Invasive Surgery Gains Ground: 3 Stocks in Focus

Applied Materials

KLA-Tencor

Lam Research

Sony

ROE helps investors distinguish profit-generating companies from profit burners and is useful in determining the financial health of a company.

5 ROE Stocks to Profit as Markets Bet on Imminent Trade Deal

Kalamazoo, Michigan, Dec.  04, 2019  (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.575 per share payable on January 31, 2020 to shareholders of record at the close of business on December 31, 2019, representing an increase of approximately 11% versus the prior year and the previous quarter. 

Stryker increases dividend 11%, declaring a $0.575 per share quarterly dividend

Apple

Investors need to be bold enough to bet on trend-shifting consumption habits emanating from Industry 4.0, which will stand them in good stead.

Industry 4.0 to Steer MedTech to Higher Growth: A Sneak Peek

Stryker (SYK) Down 5.6% Since Last Earnings Report: Can It Rebound?

Kalamazoo, Michigan, Nov.  25, 2019  (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced today that it has priced the following senior notes: (i) €850 million aggregate principal amount of the Company’s 0.25% Notes due 2024 (the “2024 Notes”), (ii) €800 million aggregate principal amount of the Company’s 0.75% Notes due 2029 (the “2029 Notes”) and (iii) €750 million aggregate principal amount of the Company’s 1.00% Notes due 2031 (the “2031 Notes” and, collectively with the 2024 Notes and 2029 Notes, the “Notes”).  Unless previously redeemed pursuant to their terms, if applicable, the 2024 Notes will mature on December 3, 2024, the 2029 Notes will mature on March 1, 2029 and the 2031 Notes will mature on December 3, 2031.  The Notes are expected to settle on December 3, 2019, subject to the satisfaction of customary closing conditions.

Stryker announces pricing of €2.4 billion senior notes offering

ROE is often used to compare the profitability of a company with other firms in the industry ??? the higher, the better.

5 ROE Stocks to Buy as Market Basks in Trade Deal Optimism

Coty

Zoetis

These health and beauty names are struggling at the moment — and their 3 big stock charts suggest the trend could get worse.
The post 3 Big Stock Charts for Wednesday: Stryker, Zoetis, and Coty appeared first on InvestorPlace.

3 Big Stock Charts for Wednesday: Stryker, Zoetis, and Coty

Stryker Corporation - 'Striking' With The Long Term In Mind

CBRE Group

Sysco

Top 5 ROE Stocks to Profit as Market Hits Record High Levels

Wright Medical Group

Stryker announced a $4 billion plan to acquire Wright Medical Group on Monday — sending the two medical technology stocks on a divergent path in premarket trading on the stock market.

Stryker Plots $4 Billion Takeover — And Its Target Rockets 30%

Shares of Wright Medical Group N.V. WMGI, +5.82% rocketed 32% toward a 3-month high in premarket trading Monday, after the medical device company announced an agreement to be bought out by Stryker Corp.

Wright Medical's stock rockets after Stryker buyout deal for 40% premium

Kalamazoo, Michigan, Nov.  04, 2019  (GLOBE NEWSWIRE) -- Stryker (NYSE: SYK) announced today a definitive agreement to acquire all of the issued and outstanding ordinary shares of Wright Medical Group N.V. (NASDAQ: WMGI) for $30.75 per share, or a total equity value of approximately $4.0 billion and a total enterprise value of approximately $5.4 billion (including convertible notes). Wright Medical, which was founded in 1950, is a global medical device company focused on extremities and biologics.

Stryker announces definitive agreement to acquire Wright Medical

American Tower

Caterpillar

Celgene

Enbridge

Mondelez

According to the GuruFocus All-in-One Screener, the following stocks have outperformed the Standard & Poor's 500 Index over the past 12 months.

News for Stryker Stock (SYK)